Why Vaxart's Stock Is Trading Higher Today

Vaxart Inc VXRT is trading higher Monday morning after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.

"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial," said Andrei Floroiu, CEO of Vaxart.

The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.

Vaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.

Price Action: Vaxart has traded as high as $24.90 and as low as $3.50 over a 52-week period.

At last check Monday, the stock was up 13.60% at $8.17.

See also: BEST MEDICARE PRESCRIPTION DRUG PLANS

Posted In: NewsSmall CapFDAMoversTrading IdeasAndrei Floroiuwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...